Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with (a) NHS England and (b) NICE on the development of (a) multi-indication pricing, (b) outcomes-based pricing and (c) annuity deals for new treatments.
The Department has regular and ongoing dialogue with NHS England and the National Institute for Health and Care Excellence on matters related to medicines pricing and patient access to new treatments. We will consider all relevant issues in upcoming discussions with the pharmaceutical industry on medicines pricing arrangements for 2019 onwards to succeed the current Pharmaceutical Price Regulation Scheme.